Marja-Liisa Dahl - Concepedia

Concepedia

Author

Marja-Liisa Dahl

Karolinska Institutet

Also Known As

MARJA‐LIISA DAHL, Marja-Liisa Dahl

15

Publications

1.2K

Citations

13

H-Index

26

Concepts

All Affiliations

Karolinska Institutet Universidad de Extremadura Uppsala University Hospital Integrated Cardio Metabolic Centre University of Beira Interior

MD

About

Marja-Liisa Dahl is an author at Karolinska Institutet specializing in medicine, pharmacology, and pharmacogenomics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	555
2	Pharmacology	4	4	303
3	Metabolism	2	2	219
4	Health Sciences	1	1	119
5	Public Health	1	1	252

Marja-Liisa Dahl

×

13

Publications

1.2K

Citations

13

H-Index

	Year	Citations
Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish Population Ümit Yaşar, Erik Eliasson, Marja-Liisa Dahl, Biochemical and Biophysical Research Communications Genetic AnalysisAllelic VariantGenetic TestingMedicineGenetics	1999	252
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype Ming Chang, Marja-Liisa Dahl, Gunnel Tybring, Pharmacogenetics	1995	203
CYP2C19 genotype and phenotype determined by omeprazole in a Korean population Hyung‐Keun Roh, Marja-Liisa Dahl, Gunnel Tybring, Pharmacogenetics Cyp2c19 GenotypeWild Type AlleleGeneticsGenetic EpidemiologyHuman Polymorphism	1996	119
The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol* Markus Jerling, Marja-Liisa Dahl, Anna Åberg-Wistedt, Clinical Pharmacology & Therapeutics	1996	100
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers Pedro Dorado, Roland Berecz, Maria-Jes�s Norberto, European Journal of Clinical Pharmacology Cyp2c9 GenotypesMedicinePharmacogenomicsPharmacotherapyMetabolism	2003	100
Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation Phenotype Adrián LLerena, Marja-Liisa Dahl, Britta Ekqvist, Therapeutic Drug Monitoring	1992	99
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype* Karin Herrlin, Amos Massele, Mary Jande, Clinical Pharmacology & Therapeutics	1998	94
Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype Roland Berecz, Alfredo de la Rubia, Pedro Dorado, European Journal of Clinical Pharmacology Molecular PharmacologyMedicineCyp2c9 GenotypePhysiologyNicotine	2003	52
The CYP2D6 Genotype and Plasma Concentrations of Mianserin Enantiomers in Relation to Therapeutic Response to Mianserin in Depressed Japanese Patients Kazuo Mihara, Koichi Otani, Gunnel Tybring, Journal of Clinical Psychopharmacology	1997	42
Quantitative Pharmacogenetics of Nortriptyline Elin E. Kvist, Ayman Al‐Shurbaji, Marja-Liisa Dahl, Clinical Pharmacokinetics Pharmacological StudyPharmacologyQuantitative PharmacogeneticsPharmacogenomicsPharmacotherapy	2001	32

Page 1